Article excerpt
Highlighted: the sentence this signal was extracted from
Against a backdrop of losing exclusivity in the marketing of several drugs, the company Pfizer plans to reduce its workforce in France by nearly 10%. Pfizer, the American pharmaceutical giant, is once again preparing to lay off employees in France. On September 2, 2026, it presented to employee representatives a draft Employment Protection Plan (PSE) providing for the elimination of 289 positions nationwide, as confirmed by management to actu.fr.Read also Prozac shortage? Fluoxetine-based antidepressants will be scarce in pharmacies in the coming weeks. The company has some 3,000 employees in the country. In detail, 516 jobs are expected to be eliminated. In parallel, 227 are planned to be created. This leads to the net balance of 289. Management refers to a "new organization". These cuts would particularly concern "the commercial department, located at the headquarters in Paris", "field positions" and "support functions".Pfizer, which paid out 9.8 billion dollars to its shareholders worldwide in 2025, intends with this PSE to anticipate several losses of commercial exclusivity "between 2026 and 2029", synonymous with a "significant drop in revenue", according to our source in management. Several patents for the laboratory's star drugs will indeed fall into the public domain, and competitors will therefore be able to distribute generics. This is notably the case for Prevenar...
Keep reading with a free account
The rest of this article, and every signal for Pfizer, is in your free account.
